A jury must decide whether pharmaceuticals giant GlaxoSmithKline used a series of illegal tactics to delay the approval of generic versions of Flonase, a popular allergy drug, a federal judge has ruled.
The 26-page decision by U.S. District Judge Anita B. Brody in In re Flonase Antitrust Litigation marks the second time the judge has refused to grant summary judgment in GSK’s favor.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
